Most cost guides for a peptide start by admitting there’s no single price. Tesamorelin is the rare case where that statement isn’t a hedge — it’s the literal structure of the market. This is the only compound in this family that exists simultaneously as an FDA-approved, specialty-pharmacy brand drug and as a cheaper compounded product prescribed off-label. The same molecule reaches patients through two parallel channels that don’t share a price list, a payer model, or even a legal indication. Understanding tesamorelin’s cost means understanding that fork.
The two-tier price reality
Tesamorelin’s price is best understood as two separate markets rather than one range.
The first is brand-name Egrifta, made by Theratechnologies. It is FDA-approved for one thing: reducing excess abdominal fat in people with HIV-associated lipodystrophy. As a regulated specialty drug, it carries a specialty-drug price. Egrifta runs approximately $3,085 or more for a 30-day supply, which works out to over $37,000 annually without insurance coverage. Pharmacy price-guide listings put the brand in the same neighborhood — roughly $6,040 for a 60-vial brand pack, with the newer reformulated presentations priced comparably. Whichever listing you read, the brand sits firmly in the thousands-per-month bracket.
The second market is compounded tesamorelin, the same peptide prepared by a compounding pharmacy and prescribed off-label — usually through a telehealth clinic — for general visceral-fat or body-composition goals. Here the numbers collapse. Compounded tesamorelin from a telehealth clinic typically lands at $250 to $500 per month and can be prescribed off-label for visceral fat. Clinic-bundled programs vary, but the order of magnitude holds: hundreds per month, not thousands.
Note: These are two genuinely different products in a regulatory sense, even though they share an active ingredient. The brand is an approved drug with an approved indication; the compounded version is an unapproved preparation used off-label. The price gap isn’t an inefficiency to arbitrage — it tracks that distinction.
What actually drives the gap
It’s tempting to assume the brand is more expensive because it’s “better” — purer, stronger, safer. That’s not really where the money goes.
When you pay brand price, you’re funding FDA approval and everything attached to it: the pivotal clinical trials that established efficacy in HIV-lipodystrophy, federally regulated manufacturing, specialty-pharmacy cold-chain distribution, patient-support infrastructure, and the rebate and pharmacy-benefit-manager margins baked into every branded specialty drug. Reputable compounded tesamorelin can hit high assay purity, but it skips that entire apparatus. The savings are real, but so is what you give up — standardized FDA-reviewed manufacturing, an approved-indication safety dossier, and a clear regulatory home.
That trade-off is the honest version of the “compounded is cheaper” pitch. Cheaper, yes. Identical in every respect that matters? No — and a careful reader should hold both facts at once. For the broader picture of how compounding pharmacies operate and the difference between 503A and 503B facilities, see our explainer on 503A vs 503B compounding.
What the bill actually includes
A monthly tesamorelin number rarely means just the drug. When you compare quotes, you’re comparing bundles, and the bundle composition is where misleading “cheaper” claims hide.
A legitimately supervised compounded program typically covers more than a vial. It includes the medical evaluation that establishes candidacy, the prescription from a licensed provider, the compounded peptide itself from a licensed pharmacy, and some form of monitoring as the protocol continues. A clinic advertising a low headline figure may be quoting drug-only and adding consult, lab, and follow-up fees separately. To compare two clinics fairly, you need the all-in monthly figure with every component named.
For the brand route, the “extra” costs look different: prior-authorization paperwork, specialty-pharmacy handling, and whatever your plan’s specialty-tier cost-share turns out to be after coverage is applied. The mechanics of getting that prescription written and routed are covered separately in our tesamorelin prescription guide.
Insurance: narrow, and only on the approved side
Insurance enters the picture only on the brand-drug side of the fork, and even there it’s restrictive.
A plan may cover Egrifta when it’s prescribed for its approved indication — HIV-associated lipodystrophy with documented excess visceral adipose tissue, often confirmed by imaging. That coverage almost always requires prior authorization, with the prescriber submitting documentation proving medical necessity against specific diagnostic criteria. Specialty-tier placement (Tier 4 or 5 on many plans) means meaningful cost-share even when coverage is granted.
Off-label compounded tesamorelin for body composition is a different story: it sits outside any approved indication, so it is essentially never covered. That route is a cash expense by default — which is part of why telehealth clinics price it as a flat monthly program rather than billing insurance. This mirrors the broader pattern for peptides generally, where coverage clusters around approved indications and leaves wellness use entirely self-pay. Our overview of GLP-1 insurance coverage walks through the same approved-vs-off-label coverage logic in the weight-loss context.
Manufacturer assistance — real, but only for the right patient
For patients who qualify on the approved HIV indication, the sticker price overstates real out-of-pocket cost. Theratechnologies runs a patient-support program that helps with prior authorization and copay assistance, and broader medication-access services advertise dramatically reduced monthly costs for eligible enrollees. These programs can turn a four-figure list price into something far more manageable — for the specific population the drug is approved for.
The catch is eligibility. There is no equivalent assistance for off-label, anti-aging, or general fat-loss use. If you don’t have the approved HIV-lipodystrophy indication, none of these brand-side savings apply, and you’re back to the compounded cash market.
Why the cheapest “prices” aren’t a price at all
Search tesamorelin cost and you’ll find figures under $100 — sometimes under $40 per vial. These aren’t a discount on the medicine described above; they’re a different thing entirely.
Those numbers come from research-only vials sold outside the medical system. A low per-vial figure reflects an unverified product of unknown actual concentration and purity, sold without a prescription, evaluation, or pharmacy oversight. The peptide-vendor market is also riddled with mislabeling — cheaper growth-hormone-releasing peptides relabeled and sold as tesamorelin is a documented problem. Treating a research-chemical price as the “real” cost of tesamorelin compares two incomparable things: a regulated (or at least pharmacy-compounded, prescribed) medicine versus an unregulated injectable of uncertain identity. The low number isn’t the bottom of tesamorelin’s price range; it’s outside the range, because it isn’t the same transaction.
So what does tesamorelin “cost”?
The honest answer is a question back: which tesamorelin, for whom, and through what route?
- If you have HIV-associated lipodystrophy and a prescriber, brand Egrifta is roughly $3,000+/month at cash price — but manufacturer assistance and insurance can cut that substantially for the approved indication.
- If you’re pursuing off-label visceral-fat or body-composition goals through a telehealth clinic, expect a compounded program in the $250-500/month range, all cash, no insurance.
- If you’re looking at sub-$100 research vials, you’re not pricing the medicine — you’re pricing an unregulated gray-market product, and the savings come entirely from removing the safeguards.
Cost only becomes a meaningful comparison once you’ve fixed the route. For more on which route fits which situation, see how to get tesamorelin in the US, and for what tesamorelin actually does (and doesn’t) deliver for the money, our breakdown of tesamorelin benefits and its use for belly fat.
Pricing reflects publicly reported US figures as of June 2026 and can change. None of the above is medical or financial advice; only a licensed provider can determine whether tesamorelin is appropriate for you and through which legitimate route.
Frequently asked questions
How much does tesamorelin cost per month in 2026?
It depends entirely on the route. FDA-approved brand Egrifta runs roughly $3,000 or more per month at cash price. Compounded tesamorelin prescribed off-label through a telehealth clinic typically lands around $250-500/month all-in. They are the same active molecule but priced in two different worlds.
Why is brand-name Egrifta so much more expensive than compounded tesamorelin?
You are paying for FDA approval: the pivotal trials, the regulated manufacturing, the specialty-pharmacy distribution, and the rebate structure built into brand pricing. Compounded tesamorelin skips all of that, which is why it is cheaper — and also why it is unapproved and less standardized.
Does insurance cover tesamorelin?
Insurance may cover brand Egrifta only for its approved indication — HIV-associated lipodystrophy with documented excess visceral fat — and almost always requires prior authorization. Compounded tesamorelin used off-label for body composition is essentially never covered, so it is a cash expense.
Is there a cheaper way to get tesamorelin?
Manufacturer patient-support and copay-assistance programs can dramatically lower out-of-pocket cost for eligible patients with the approved HIV indication. There is no comparable assistance for off-label or cosmetic use; that is full cash price every time.
Why are 'tesamorelin' prices online sometimes under $100?
Those are research-only vials sold outside the medical system, not a legitimate access route. A low per-vial price reflects an unverified, unregulated product of unknown purity and concentration — not a bargain on a prescription medicine.